Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Bengaluru"

180 News Found

Max Lab partners with Stepcare to expand in Bengaluru
Healthcare | July 23, 2025

Max Lab partners with Stepcare to expand in Bengaluru

This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas


Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
Drug Approval | July 17, 2025

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms


USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
Drug Approval | June 17, 2025

USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru

The inspection concluded successfully, with the facility found to be in compliance with the required regulations


OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru
Drug Approval | April 11, 2025

OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru

This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance


NURA AI Health Screening Centre Bengaluru celebrates 4th anniversary of transforming lives through early detection
News | February 08, 2025

NURA AI Health Screening Centre Bengaluru celebrates 4th anniversary of transforming lives through early detection

Plans underway to expand screening capacity by 50% for greater accessibility


Merck inaugurates expansion of its Peenya facility in Bengaluru
News | January 25, 2025

Merck inaugurates expansion of its Peenya facility in Bengaluru

Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region


USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
News | November 11, 2024

USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI

The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature


USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru
News | July 29, 2024

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants


Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
News | May 17, 2024

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market

Cresset’s new India site will support the growing demands of Cresset’s APAC customer base